Skip to content

GlobeStar Therapeutics Corp: 10-Q filed 2015-02-17

What GlobeStar Therapeutics Corp reported in its quarterly report filed 2015-02-17 (fiscal Q1 2015): 24 published measures, 53 facts as tagged in accession 0001161697-15-000086.

This filing

Form
10-Q (quarterly report)
Filed
2015-02-17
Fiscal period
fiscal Q1 2015
Accession
0001161697-15-000086 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GlobeStar Therapeutics Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-12-31472,855USD
At 2014-09-30477,603USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-12-31603,057USD
At 2014-09-30582,038USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-12-31-130,202USD
At 2014-09-30-104,435USD
At 2013-09-30245,282USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-12-312,832USD
At 2014-09-301,211USD
At 2013-12-3129,659USD
At 2012-09-30127,748USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-225,642USD92
2013-10-01 to 2014-09-30-1,245,170USD365
2013-10-01 to 2013-12-31-355,521USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-68,897USD92
2013-10-01 to 2013-12-31-117,240USD92

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2014-10-01 to 2014-12-3119,161USD92
2013-10-01 to 2013-12-3132,210USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2014-10-01 to 2014-12-3170,620USD92
2013-10-01 to 2013-12-3144,650USD92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-102USD92
2013-10-01 to 2013-12-31-25,499USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-12-31-3,582,417USD
At 2014-09-30-3,356,775USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-98,209USD92
2013-10-01 to 2013-12-31-159,923USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-12-3131,303USD
At 2014-09-3029,262USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-10-01 to 2014-12-31127,433USD92
2013-10-01 to 2013-12-31195,598USD92

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-12-31579,468USD
At 2014-09-30560,760USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-12-31268,390USD
At 2014-09-30245,876USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2014-12-3116,311USD
At 2014-09-3015,891USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-12-3128,020,137shares
At 2014-09-3028,020,137shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-12-313,432,015USD
At 2014-09-303,232,399USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2014-12-3117,398USD
At 2014-09-3017,379USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2014-10-01 to 2014-12-31-225,623USD92
2013-10-01 to 2014-09-30-1,227,791USD365
2013-10-01 to 2013-12-31-350,881USD92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-10-01 to 2014-12-31104,426USD92
2013-10-01 to 2013-12-31165,068USD92

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2014-10-01 to 2014-12-316,786USD92
2013-10-01 to 2013-12-3122,900USD92

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2014-10-01 to 2014-12-31420USD92
2013-10-01 to 2013-12-3116,374USD92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-10-01 to 2014-12-3122,514USD92
2013-10-01 to 2013-12-3164,763USD92

Inspect the source

Entity
GlobeStar Therapeutics Corp / CIK 0001502152
Captured
2026-09-21T17:19:31.788Z
SEC response SHA-256
6be36a03e8f75354b6b3cf653d7b4e1bb0d8a85378e8b575eedf967d0fac66f7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001502152.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))